brolucizumab-dbll
Trade name: Beovu
mAbapproved
Approved
Oct 7, 2019
Brolucizumab sold under trade name Beovu among others, is a humanized single-chain antibody fragment for the treatment of neovascular (wet) age-related macular degeneration (AMD). — Wikipedia
Clinical trial activity
40 trials · 13 clinical orgs · 1 marketing orgs
Phase 1
2
Phase 2
27
Phase 3
22
Phase 4
10
Earliest trial started Oct 1, 2010 (NCT01304693)
Timeline
Indications
Approved for
Studied for
- Choroidal Neovascularization · Phase 3
- Diabetes Mellitus · Phase 3
- Diabetic Retinopathy · Phase 3
- Eye Diseases · Phase 4
- Macular Degeneration · Phase 4
- Macular Edema · Phase 4
- Polypoidal Choroidal Vasculopathy · Phase 3
- Retinal Degeneration · Phase 4
- Retinal Diseases · Phase 4
- Retinal Dystrophies · Phase 4
- Retinal Vein Occlusion · Phase 3
- Wet Macular Degeneration · Phase 4
Mechanism of action
- Vascular endothelial growth factor AINHIBITOR
VEGFA inhibitor
Binds to all isoforms of VEGF-A including VEGF165.
Approval history
- approvedOct 7, 2019
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
- Multi-specific
- No
Oral
No
Parenteral
Yes
Topical
No
Sources
- ChEMBLCHEMBL3707357 ↗
- WikipediaBrolucizumab ↗
- NCATSXSZ53G39H5 ↗
Also known as
- esba1008
- lmg324
- rth258
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05959304 | Phase 4 | Dec 11, 2024 | Novartis |
| NCT06498050 | Phase 4 | Jul 9, 2024 | Shantou University |
| NCT07096713 | N/A | Jan 1, 2024 | Benha University |
| NCT05666804 | Phase 3 | Jan 31, 2023 | Novartis |
| NCT05672979 | Phase 3 | Jan 1, 2023 | Novartis, Yeungnam University |
| NCT05710471 | Phase 4 | Jul 25, 2022 | The University of Hong Kong |
| NCT05269966 | Phase 4 | Mar 10, 2022 | Novartis |
| NCT04932980 | N/A | Sep 30, 2021 | medignition AG, University of Bern |
| NCT04774926 | Phase 4 | Sep 15, 2021 | Novartis |
| NCT04697953 | Phase 3 | May 31, 2021 | Novartis |
| NCT04679935 | Phase 4 | Jan 29, 2021 | Novartis |
| NCT04955171 | Phase 3 | Jan 12, 2021 | Benha University |
| NCT04698850 | Phase 4 | Jan 4, 2021 | Teaching Hospital Královské Vinohrady (FNKV) |
| NCT04597632 | Phase 4 | Dec 23, 2020 | Novartis |
| NCT04690062 | Phase 4 | Oct 25, 2020 | Benha University |
| NCT04278417 | Phase 3 | May 1, 2020 | Novartis |
| NCT04264819 | Phase 3 | Apr 15, 2020 | Novartis |
| NCT04287348 | Phase 4 | Feb 29, 2020 | Novartis, Vista Klinik |
| NCT04239027 | Phase 3 | Feb 15, 2020 | Novartis |
| NCT04047472 | Phase 3 | Sep 17, 2019 | Novartis |
Showing 20 of 40 trials
Page 1 / 2
Organizations
Research & Development (13)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 27 | 23 | 3 | 2015 |
| Alcon | For profit | 7 | 7 | 2 | 2010 |
| Benha University | Academic/Hospital | 3 | 3 | 3 | 2020 |
| medignition AG | For profit | 1 | 0 | 1 | 2021 |
| Nanyang Technological University | Academic/Hospital | 1 | 0 | 1 | 2019 |
| National University of Singapore | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Shantou University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Singapore National Eye Centre | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Teaching Hospital Královské Vinohrady (FNKV) | Academic/Hospital | 1 | 1 | 1 | 2021 |
| The University of Hong Kong | Academic/Hospital | 1 | 1 | 1 | 2022 |
| University of Bern | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Vista Klinik | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Yeungnam University | Academic/Hospital | 1 | 1 | 1 | 2023 |
13 organizations
Page 1 / 1